Thrombocytosis differential diagnosis: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. {{Thrombocytosis}} ==References== {{reflis...")
 
 
(54 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
{{Thrombocytosis}}
{{Thrombocytosis}}


==References==
{{CMG}}; {{AE}} {{SSH}}
{{reflist|2}}
 
{{WH}}
==Overview==
{{WS}}


[[Category:Blood disorders]]
==Thrombocytosis Differential Diagnosis==
[[Category:Disease]]
'''Differentiating the diseases that can cause thrombocytosis :'''
[[Category:Hematology]]
[[Category:Oncology]]


{|
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
! colspan="2" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! colspan="3" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mechanism
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
! colspan="9" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations
! colspan="8" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para−clinical findings
! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms
| colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs
|-
! colspan="7" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
|-
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Increased megakaryocyte proliferation
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Accelerated platelet release
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Reduced platelet turnover
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
|-
! rowspan="8" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Autonomous thrombocytosis
! rowspan="6" align="center" style="background:#DCDCDC;" |Hematologic malignancies
! align="center" style="background:#DCDCDC;" |[[Essential thrombocytosis|Essential thrombocythemia]]<ref name="Brière2007">{{cite journal|last1=Brière|first1=Jean B|journal=Orphanet Journal of Rare Diseases|volume=2|issue=1|year=2007|pages=3|issn=17501172|doi=10.1186/1750-1172-2-3}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* Acquired mutation of ''[[Janus kinase|JAK2]], CALR,'' or ''MPL''
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Mean age >60 years old, female > male
| align="Left" style="background:#F5F5F5;" + |
* Vascular occlusive events and [[Bleeding|hemorrhages]]
| align="center" style="background:#F5F5F5;" + |±
| align="Left" style="background:#F5F5F5;" + |
* Flushing
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="Left" style="background:#F5F5F5;" + |
* [[Erythromelalgia]]
* [[Transient ischemic attack|Transient ischemic attacks]]
* [[Priapism]]
* Decreased [[visual acuity]]
| align="center" style="background:#F5F5F5;" + |↑↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* Large [[Platelet|platelets]]
* [[Megakaryocyte]] fragments
* [[Platelet]] aggregates
| align="Left" style="background:#F5F5F5;" + |
* Increased cellularity
* [[Hyperplasia]] and clustering of [[megakaryocytes]]
* [[Bone marrow]] [[reticulin]] may be increased with no [[collagen]] [[fibrosis]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="Left" style="background:#F5F5F5;" + |
* [[Splenomegaly]] on abdominal CT
* [[VTE]] on spiral chest CT
* [[Deep vein thrombosis|DVT]] on ultrasound
| align="center" style="background:#F5F5F5;" + |[[Bone marrow examination|Bone marrow biopsy]]
| align="Left" style="background:#F5F5F5;" + |
* Thrombo-hemorrhagic complications
|-
! align="center" style="background:#DCDCDC;" |[[Polycythemia vera]]<ref name="ArberOrazi2016">{{cite journal|last1=Arber|first1=D. A.|last2=Orazi|first2=A.|last3=Hasserjian|first3=R.|last4=Thiele|first4=J.|last5=Borowitz|first5=M. J.|last6=Le Beau|first6=M. M.|last7=Bloomfield|first7=C. D.|last8=Cazzola|first8=M.|last9=Vardiman|first9=J. W.|title=The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia|journal=Blood|volume=127|issue=20|year=2016|pages=2391–2405|issn=0006-4971|doi=10.1182/blood-2016-03-643544}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* Acquired mutation of ''[[JAK2]]''
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Mean age >60 years old
| align="Left" style="background:#F5F5F5;" + |
* Family history of [[polycythemia vera]]
* Ashkenazi Jewish descent
| align="center" style="background:#F5F5F5;" + | -
| align="Left" style="background:#F5F5F5;" + |
* Facial plethora
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="Left" style="background:#F5F5F5;" + |
* [[Erythromelalgia]]
* [[Itch|Pruritus]]
* [[Tinnitus]]
* [[Blurred vision]]
* [[Lymphadenopathy]]
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑↑
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* Panmyelosis including prominent [[Red blood cell|erythroid]], [[granulocyte]], and [[megakaryocyte]] proliferation
| align="Left" style="background:#F5F5F5;" + |
* Panmyelosis including prominent [[Red blood cell|erythroid]], [[granulocyte]], and [[megakaryocyte]] proliferation
* Pleomorphic, mature [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |
* [[Splenomegaly]] or splenic [[Infarction|infarcts]] on imaging
* Increased radiographic attenuation of [[cerebral arteries]], veins and dural [[sinuses]] on [[Computed tomography|CT scan]] or [[Magnetic resonance imaging|MRI]]
| align="center" style="background:#F5F5F5;" + |[[Bone marrow examination|Bone marrow biopsy]]
| align="Left" style="background:#F5F5F5;" + |
* Thrombo-hemorrhagic complications
|-
! align="center" style="background:#DCDCDC;" |[[Myelofibrosis|Primary myelofibrosis]]<ref name="TefferiLasho2012">{{cite journal|last1=Tefferi|first1=Ayalew|last2=Lasho|first2=Terra L.|last3=Jimma|first3=Thitina|last4=Finke|first4=Christy M.|last5=Gangat|first5=Naseema|last6=Vaidya|first6=Rakhee|last7=Begna|first7=Kebede H.|last8=Al-Kali|first8=Aref|last9=Ketterling|first9=Rhett P.|last10=Hanson|first10=Curtis A.|last11=Pardanani|first11=Animesh|title=One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience|journal=Mayo Clinic Proceedings|volume=87|issue=1|year=2012|pages=25–33|issn=00256196|doi=10.1016/j.mayocp.2011.11.001}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* [[Bone marrow]] fibrosis
* [[Mutation]] in ''[[Janus kinase|JAK2]], CALR'', or ''MPL''
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Mean age >60 years old, male> female
| align="Left" style="background:#F5F5F5;" + |
* Other [[Myeloproliferative neoplasm|myeloproliferative]] disorders
* [[Radioactive contamination|Radiation exposure]]
* Chemicals exposure
| align="center" style="background:#F5F5F5;" + | -
| align="Left" style="background:#F5F5F5;" + |
* [[Pallor]]
* [[Bruising]]
* [[Nodules|Skin nodules]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="Left" style="background:#F5F5F5;" + |
* [[Fatigue]]
* [[Abdominal pain]]
* Early satiety
* [[Dyspnea]]
* [[Lymphadenopathy]]
| align="center" style="background:#F5F5F5;" + |↑/↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="Left" style="background:#F5F5F5;" + |
* Decreased number of [[Red blood cell|erythroid]], [[granulocyte]], and [[megakaryocyte]] proliferation
| align="Left" style="background:#F5F5F5;" + |
* Proliferation and atypia of [[megakaryocytes]]
* Reticulin or [[Collagen|collagen fibrosis]]
* Hypercellular [[bone marrow]]
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* Diffuse bone [[sclerosis]] on [[CT angiography|CT]]
| align="center" style="background:#F5F5F5;" + |[[Bone marrow examination|Bone marrow biopsy]]
| align="Left" style="background:#F5F5F5;" + |
* Thrombo-hemorrhagic complications
* Variable risk for development of [[acute leukemia]]
|-
! align="center" style="background:#DCDCDC;" |[[Chronic myelogenous leukemia|Chronic myeloid leukemia]]<ref name="ThompsonKantarjian2015">{{cite journal|last1=Thompson|first1=Philip A.|last2=Kantarjian|first2=Hagop M.|last3=Cortes|first3=Jorge E.|title=Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015|journal=Mayo Clinic Proceedings|volume=90|issue=10|year=2015|pages=1440–1454|issn=00256196|doi=10.1016/j.mayocp.2015.08.010}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* Translocation (9;22), the [[Philadelphia chromosome]]
* [[BCR/ABL|''BCR-ABL1'' oncogene]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Mean age >50 years old, male> female
| align="Left" style="background:#F5F5F5;" + |History of exposure to:
* [[Ionizing radiation]]
* [[Formaldehyde]]
* [[Benzene]]
| align="center" style="background:#F5F5F5;" + | +
| align="Left" style="background:#F5F5F5;" + |
* [[Pallor]]
* [[Bruises]]
* [[Petechiae]]
* [[Ulcers]]
* [[Vesicles]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="Left" style="background:#F5F5F5;" + |
* [[Fatigue]]
* [[Abdominal pain]]
* Early satiety
* [[Dyspnea]]
* [[Lymphadenopathy]]
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* Immature [[White blood cells|leukocytes]]
* Leukemic blasts
* Leukoerythroblastic features
* Giant [[platelets]]
* Blast crisis
| align="Left" style="background:#F5F5F5;" + |
* ↑ Proportion of metamyelocytes and other [[white blood cells]] at various stages of maturation
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* Enlarged [[Lymph node|lymph nodes]] and [[splenomegaly]] on [[Computed tomography|CT scan]]
| align="center" style="background:#F5F5F5;" + |[[Bone marrow examination|Bone marrow biopsy]]
| align="Left" style="background:#F5F5F5;" + |
* Increase of immature myeloid cells
|-
! align="center" style="background:#DCDCDC;" + |[[Acute myeloid leukemia]]<ref name="Rose-InmanKuehl2014">{{cite journal|last1=Rose-Inman|first1=Hayley|last2=Kuehl|first2=Damon|title=Acute Leukemia|journal=Emergency Medicine Clinics of North America|volume=32|issue=3|year=2014|pages=579–596|issn=07338627|doi=10.1016/j.emc.2014.04.004}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* Unknown
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Median age of 63 years old
| align="Left" style="background:#F5F5F5;" + |
* History of [[hematological]] disorder
* History of [[chemotherapy]] and  [[ionizing radiation]]
| align="center" style="background:#F5F5F5;" + | +
| align="Left" style="background:#F5F5F5;" + |
* [[Pallor]]
* [[Chloroma|Leukemia cutis]]
* [[Bruising]]
* [[Petechia|Petechiae]]
* [[Ecchymosis]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="Left" style="background:#F5F5F5;" + |
* [[Fatigue]]
* Bone [[tenderness]]
* Early satiety
| align="center" style="background:#F5F5F5;" + |↑/↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↑/↓
| align="Left" style="background:#F5F5F5;" + |
* [[Leukemic]] blasts
* Leukoerythroblastic features
* Giant [[Platelet|platelets]]
| align="Left" style="background:#F5F5F5;" + |
* "Dry tap" on aspiration
* [[Leukemic]] cells
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |[[Bone marrow examination]] + clinical manifestation
| align="Left" style="background:#F5F5F5;" + |
* [[Infection|Infections]] of variable severity
* [[Nerve palsy|Cranial nerve palsy]]
|-
! align="center" style="background:#DCDCDC;" + |[[Myelodysplastic syndrome|Myelodysplastic syndromes]]<ref name="NatelsonPyatt2013">{{cite journal|last1=Natelson|first1=Ethan A.|last2=Pyatt|first2=David|title=Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog|journal=Advances in Hematology|volume=2013|year=2013|pages=1–11|issn=1687-9104|doi=10.1155/2013/309637}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* Unknown
* [[Mutation]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | ±
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Elderly
| align="Left" style="background:#F5F5F5;" + |Exposure to:
* [[Chemotherapy]]
* [[Radiation therapy]]
* [[Tobacco smoking|Tobacco smoke]]
| align="center" style="background:#F5F5F5;" + | ±
| align="left" style="background:#F5F5F5;" + |
* [[Petechia|Petechiae]]
* [[Purpura]]
* Diffuse erythematous [[rash]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="Left" style="background:#F5F5F5;" + |
* [[Shortness of breath]]
* [[Fatigue]]
| align="center" style="background:#F5F5F5;" + |↑/↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="Left" style="background:#F5F5F5;" + |
* Large platelets
* Ovalomacrocytosis
* Basophilic stippling
* [[Howell-Jolly body]]
* Pelger-Huet anomaly
* Ring [[Sideroblastic|sideroblasts]]
| align="Left" style="background:#F5F5F5;" + |
* Impaired [[myeloid]] maturation
* [[Congenital dyserythropoietic anemia|Dyserythropoiesis]]
* Dysgranulopoiesis
* Dysmegakaryocytopoiesis
* Hypercellular [[bone marrow]]
* [[Fibrosis]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |[[Bone marrow examination]] + clinical manifestation
| align="Left" style="background:#F5F5F5;" + |
* [[Thrombosis]] at unusual sites
* [[Thrombosis]] in younger patients
* Might transformed to [[acute leukemia]]
|-
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Increased megakaryocyte proliferation
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Accelerated platelet release
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Reduced platelet turnover
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Familial thrombocytosis<ref name="Ding2004">{{cite journal|last1=Ding|first1=J.|title=Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin|journal=Blood|volume=103|issue=11|year=2004|pages=4198–4200|issn=0006-4971|doi=10.1182/blood-2003-10-3471}}</ref><ref name="WiestnerPadosch2000">{{cite journal|last1=Wiestner|first1=A.|last2=Padosch|first2=S. A.|last3=Ghilardi|first3=N.|last4=Cesar|first4=J. M.|last5=Odriozola|first5=J.|last6=Shapiro|first6=A.|last7=Skoda|first7=R. C.|title=Hereditary thrombocythaemia is a genetically heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary thrombocythaemia|journal=British Journal of Haematology|volume=110|issue=1|year=2000|pages=104–109|issn=0007-1048|doi=10.1046/j.1365-2141.2000.02169.x}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* [[Mutation]] in ''TPO'' and ''MPL''
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Rare familial disease, middle age male and female
| align="Left" style="background:#F5F5F5;" + |
* Family history of [[thrombocytosis]]
| align="center" style="background:#F5F5F5;" + | -
| align="left" style="background:#F5F5F5;" + |
* Normal
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="Left" style="background:#F5F5F5;" + |
* Giant [[Platelet|platelets]]
* [[Platelet]] conglomerates
* Bizarre forms
* [[Myelofibrosis|Megakaryocytic]] fragments
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |Genetic study
| align="Left" style="background:#F5F5F5;" + |
* Polyclonal hematopoiesis
* Familial [[polycythemia vera]]
* Familial [[Myelofibrosis|primary myelofibrosis]]
|-
! rowspan="20" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Reactive thrombocytosis
! align="center" style="background:#DCDCDC;" + |[[Anemia]]/
[[Bleeding|blood loss]]<ref name="Kuter1996">{{cite journal|last1=Kuter|first1=David J.|title=The Physiology of Platelet Production|journal=Stem Cells|volume=14|issue=S1|year=1996|pages=88–101|issn=10665099|doi=10.1002/stem.5530140711}}</ref>
| align="left" style="background:#DCDCDC;" |
* [[Iron deficiency anemia|Iron deficiency]]
* [[Bleeding|Blood loss]]
* [[Hemolysis]]
| align="Left" style="background:#F5F5F5;" + |
* Unknown
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="Left" style="background:#F5F5F5;" + |
* History of [[bleeding]] or [[Iron deficiency anemia|iron deficiency]]
| align="center" style="background:#F5F5F5;" + | -
| align="Left" style="background:#F5F5F5;" + |
* [[Pallor]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Depends on the etilogy
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="Left" style="background:#F5F5F5;" + |
* [[Microcytic anemia]]
* [[Myelofibrosis|Megakaryocytic]] fragments
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |Clinical manifestation
| align="Left" style="background:#F5F5F5;" + |
* Required iron studies
|-
! rowspan="3" align="center" style="background:#DCDCDC;" |[[Infection]]
! align="center" style="background:#DCDCDC;" |Chronic [[Infection|infections]]
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="Left" style="background:#F5F5F5;" + |
* History of [[immunodeficiency]]
| align="center" style="background:#F5F5F5;" + | +
| align="Left" style="background:#F5F5F5;" + |
* [[Pallor]]
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |Depends on the etilogy
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* Microcytic [[anemia]]
* [[Myelofibrosis|Megakaryocytic]] fragments
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="Left" style="background:#F5F5F5;" + |
* Depends on the etiology
| align="center" style="background:#F5F5F5;" + |Culture
| align="center" style="background:#F5F5F5;" + |Depends on the etilogy
|-
! align="center" style="background:#DCDCDC;" + |[[Tuberculosis]]
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="Left" style="background:#F5F5F5;" + |
* History of  close contact
| align="center" style="background:#F5F5F5;" + | +
| align="Left" style="background:#F5F5F5;" + |
* Cachectic
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* Large [[platelets]]
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="Left" style="background:#F5F5F5;" + |
* Cavitation on chest imaging
| align="center" style="background:#F5F5F5;" + |Clinical manifestation+ culture
| align="center" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |Acute bacterial and viral infections
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="Left" style="background:#F5F5F5;" + |
* History of  close contact
| align="center" style="background:#F5F5F5;" + | +
| align="Left" style="background:#F5F5F5;" + |
* Acutely ill
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Depends on the etilogy
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* Large [[platelets]]
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="Left" style="background:#F5F5F5;" + |
* Depends on the etiology
| align="center" style="background:#F5F5F5;" + |Clinical manifestation+ culture
| align="Left" style="background:#F5F5F5;" + |
* Depends on the etiology
|-
! rowspan="3" align="center" style="background:#DCDCDC;" |[[Inflammation]]
! align="center" style="background:#DCDCDC;" |[[Vasculitis|Vasculitides]]<ref name="pmid82963">{{cite journal |vauthors=Hamblin T, Oscier D |title=Polyarteritis presenting with thrombocytosis and palliated by plasma exchange |journal=Postgrad Med J |volume=54 |issue=635 |pages=615–7 |date=September 1978 |pmid=82963 |pmc=2425233 |doi= |url=}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* Unknown
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="Left" style="background:#F5F5F5;" + |
* Family history of rheumatologic disorders
| align="center" style="background:#F5F5F5;" + | +
| align="Left" style="background:#F5F5F5;" + |
* Acutely ill
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="Left" style="background:#F5F5F5;" + |
* [[Arthritis]]
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* [[Microcytic anemia]]
* [[Myelofibrosis|Megakaryocytic]] fragments
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + |Nl to ↑
| align="center" style="background:#F5F5F5;" + |Nl to ↑
| align="Left" style="background:#F5F5F5;" + |
* Depends on the type
| align="center" style="background:#F5F5F5;" + |Clinical manifestation+ culture
| align="Left" style="background:#F5F5F5;" + |
* Depends on the type
|-
! align="center" style="background:#DCDCDC;" + |[[Acute pancreatitis]]
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="Left" style="background:#F5F5F5;" + |
* [[Long-term effects of alcohol|Alcohol consumption]]
* [[Gallstone disease|Gallstone]]
* [[Hyperlipoproteinemia|Hypertriglyceridemia]]
* [[Obesity]]
| align="center" style="background:#F5F5F5;" + | +
| align="Left" style="background:#F5F5F5;" + |
* Acutely ill
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="Left" style="background:#F5F5F5;" + |
* [[Tenderness (medicine)|Abdominal tenderness]]
* [[Nausea and vomiting|N/V]]
* [[Dyspnea]]
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* Large [[platelets]]
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + |Nl to ↑
| align="center" style="background:#F5F5F5;" + |Nl to ↑
| align="Left" style="background:#F5F5F5;" + |
* Diffusely enlarged and hypoechoic [[pancreas]] on abdominal [[ultrasound]]
* Focal or diffuse enlargement of the [[pancreas]] with heterogeneous enhancement on abdominal [[Computed tomography|CT scan]]
| align="center" style="background:#F5F5F5;" + |Clinical manifestation
| align="Left" style="background:#F5F5F5;" + |
* Rarely progress to severe [[inflammation]] and [[necrosis]]
* Organ failure
|-
! align="center" style="background:#DCDCDC;" |[[Cancer|Malignancy]]<ref name="YangJiang2018">{{cite journal|last1=Yang|first1=Chen|last2=Jiang|first2=Hui|last3=Huang|first3=Shaozhuo|last4=Hong|first4=Hui|last5=Huang|first5=Xiaowen|last6=Wang|first6=Xiaojie|last7=Liao|first7=Weixin|last8=Wang|first8=Xueyi|last9=Chen|first9=Xuewen|last10=Jiang|first10=Liming|title=The prognostic role of pretreatment thrombocytosis in gastric cancer|journal=Medicine|volume=97|issue=31|year=2018|pages=e11763|issn=0025-7974|doi=10.1097/MD.0000000000011763}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
* Accelerated [[platelet]] release
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |Any
| align="Left" style="background:#F5F5F5;" + |
* Prior malignancy
* Exposure to chemicals
* Family history of malignancy
| align="center" style="background:#F5F5F5;" + | +
| align="Left" style="background:#F5F5F5;" + |
* Cachectic
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + |Depends on the type
| align="center" style="background:#F5F5F5;" + | -
| align="Left" style="background:#F5F5F5;" + |
* Tenderness
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* Microcytic [[anemia]]
* [[Myelofibrosis|Megakaryocytic]] fragments
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + |Nl to ↑
| align="center" style="background:#F5F5F5;" + |Nl to ↑
| align="Left" style="background:#F5F5F5;" + |
* Depends on the type
| align="center" style="background:#F5F5F5;" + |[[Biopsy]]
| align="Left" style="background:#F5F5F5;" + |
* Potential effective predictor of overall survival
* [[Venous thromboembolism]]
|-
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Increased megakaryocyte proliferation
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Accelerated platelet release
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Reduced platelet turnover
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
! rowspan="3" align="center" style="background:#DCDCDC;" + |Tissue damage
! align="center" style="background:#DCDCDC;" + |[[Burns|Thermal burns]]<ref name="DinsdaleDevi2017">{{cite journal|last1=Dinsdale|first1=R. J.|last2=Devi|first2=A.|last3=Hampson|first3=P.|last4=Wearn|first4=C. M.|last5=Bamford|first5=A. L.|last6=Hazeldine|first6=J.|last7=Bishop|first7=J.|last8=Ahmed|first8=S.|last9=Watson|first9=C.|last10=Lord|first10=J. M.|last11=Moiemen|first11=N.|last12=Harrison|first12=P.|title=Changes in novel haematological parameters following thermal injury: A prospective observational cohort study|journal=Scientific Reports|volume=7|issue=1|year=2017|issn=2045-2322|doi=10.1038/s41598-017-03222-w}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* Accelerated [[platelet]] release
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="Left" style="background:#F5F5F5;" + |
* Thermal burn
| align="center" style="background:#F5F5F5;" + | +
| align="Left" style="background:#F5F5F5;" + |
* Acutely ill
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |±
| align="Left" style="background:#F5F5F5;" + |
* [[Fatigue]]
* [[Tenderness]]
* [[Burn]]
* [[Dyspnea]]
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* [[Myelofibrosis|Megakaryocytic]] fragments
* Large numbers of microspherocytes
| align="Left" style="background:#F5F5F5;" + |
* Increased production of [[Neutrophil|neutrophils]]
| align="center" style="background:#F5F5F5;" + |Nl to ↑
| align="center" style="background:#F5F5F5;" + |Nl to ↑
| align="Left" style="background:#F5F5F5;" + |
* Depend on the involvement
| align="center" style="background:#F5F5F5;" + |Clinical manifestation
| align="Left" style="background:#F5F5F5;" + |
* [[Sepsis]]
|-
! align="center" style="background:#DCDCDC;" + |[[Physical trauma|Trauma]]<ref name="SalimHadjizacharia2009">{{cite journal|last1=Salim|first1=Ali|last2=Hadjizacharia|first2=Pantelis|last3=DuBose|first3=Joseph|last4=Kobayashi|first4=Leslie|last5=Inaba|first5=Kenji|last6=Chan|first6=Linda S.|last7=Margulies|first7=Daniel R.|title=What is the Significance of Thrombocytosis in Patients With Trauma?|journal=The Journal of Trauma: Injury, Infection, and Critical Care|volume=66|issue=5|year=2009|pages=1349–1354|issn=0022-5282|doi=10.1097/TA.0b013e318191b8af}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* Accelerated [[platelet]] release
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="Left" style="background:#F5F5F5;" + |
* [[Physical trauma]]
* Accident
| align="center" style="background:#F5F5F5;" + |±
| align="Left" style="background:#F5F5F5;" + |
* Acutely ill
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="Left" style="background:#F5F5F5;" + |
* [[Tenderness]]
* [[Bone fracture|Fracture]]
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* [[Myelofibrosis|Megakaryocytic]] fragments
* Large numbers of microspherocytes
| align="Left" style="background:#F5F5F5;" + |
* Increased production of [[Neutrophil|neutrophils]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="Left" style="background:#F5F5F5;" + |
* Depend on the involvement
* [[Bone fracture|Fracture]] on X-rays
| align="center" style="background:#F5F5F5;" + |Clinical manifestation
| align="Left" style="background:#F5F5F5;" + |
* [[Sepsis]]
* Associated with higher rates of complications
|-
! align="center" style="background:#DCDCDC;" + |[[ST elevation myocardial infarction|Myocardial infarction]]<ref name="NanavatiPatel2012">{{cite journal|last1=Nanavati|first1=Amit|last2=Patel|first2=Nainesh|last3=Burke|first3=James|title=Thrombocytosis and Coronary Occlusion|journal=JACC: Cardiovascular Interventions|volume=5|issue=6|year=2012|pages=e18–e19|issn=19368798|doi=10.1016/j.jcin.2011.12.018}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* Accelerated [[platelet]] release
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Elderly
| align="Left" style="background:#F5F5F5;" + |
* [[Acute coronary syndromes|Acute coronary syndrome]]
* [[Diabetes mellitus]]
| align="center" style="background:#F5F5F5;" + |±
| align="Left" style="background:#F5F5F5;" + |
* Acutely ill
* Diaphoretic
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="Left" style="background:#F5F5F5;" + |
* [[Chest pain]]
* [[Dyspnea]]
* [[Nausea and vomiting|N/V]]
* [[Coma]]
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* [[Myelofibrosis|Megakaryocytic]] fragments
* Large numbers of microspherocytes
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="Left" style="background:#F5F5F5;" + |
* Hypokinetic heart on [[Echocardiography|echocardiogram]]
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + enzymes elevation
| align="Left" style="background:#F5F5F5;" + |
* [[Pulmonary edema|Acute pulmonary edema]]
* Poor prognosis
|-
! rowspan="5" align="center" style="background:#DCDCDC;" + |[[Medication]]<ref name="pmid8473359">{{cite journal |vauthors=Frye JL, Thompson DF |title=Drug-induced thrombocytosis |journal=J Clin Pharm Ther |volume=18 |issue=1 |pages=45–8 |date=February 1993 |pmid=8473359 |doi= |url=}}</ref>
! align="center" style="background:#DCDCDC;" + |[[Vincristine sulfate|Vincristine]]<ref name="FeliuCervantes1980">{{cite journal|last1=Feliu|first1=E.|last2=Cervantes|first2=F.|last3=Blade|first3=J.|last4=Rozman|first4=C.|title=Thrombocytosis in Quiescent Chronic Granulocytic Leukaemia after Vincristine and 6-Mercaptopurine Therapy|journal=Acta Haematologica|volume=64|issue=4|year=1980|pages=224–226|issn=0001-5792|doi=10.1159/000207258}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* Increased [[Megakaryocyte|megakaryocytic]] differentiation
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="Left" style="background:#F5F5F5;" + |
* [[Cancer|Malignancy]]
* Drug consumption
| align="center" style="background:#F5F5F5;" + | -
| align="Left" style="background:#F5F5F5;" + |
* Cachectic
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="Left" style="background:#F5F5F5;" + |
* [[Abdominal pain]]
* [[Diarrhea]]
* [[Dizziness]]
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* [[Myelofibrosis|Megakaryocytic]] fragments
* Large numbers of microspherocytes
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + |Nl to ↑
| align="center" style="background:#F5F5F5;" + |Nl to ↑
| align="Left" style="background:#F5F5F5;" + |
* Depends on the etiology
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + history of drug consumption
| align="Left" style="background:#F5F5F5;" + |
* [[Neuropathy]]
|-
! align="center" style="background:#DCDCDC;" + |[[Epinephrine]]<ref name="pmid9461228">{{cite journal |vauthors=Spalding A, Vaitkevicius H, Dill S, MacKenzie S, Schmaier A, Lockette W |title=Mechanism of epinephrine-induced platelet aggregation |journal=Hypertension |volume=31 |issue=2 |pages=603–7 |date=February 1998 |pmid=9461228 |doi= |url=}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* Unknown
* Activation of chloride transport
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="Left" style="background:#F5F5F5;" + |
* [[Anaphylaxis]]
* [[Respiratory disease|Respiratory diseases]]
| align="center" style="background:#F5F5F5;" + | -
| align="Left" style="background:#F5F5F5;" + |
* Acutely ill
* Diaphoretic
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="Left" style="background:#F5F5F5;" + |
* [[Dizziness]]
* [[Tremor]]
* [[Anxiety]]
* [[Dyspnea]]
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* [[Myelofibrosis|Megakaryocytic]] fragments
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="Left" style="background:#F5F5F5;" + |
* Depends on the etiology
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + history of drug consumption
| align="Left" style="background:#F5F5F5;" + |
* [[Thrombosis|Thromboembolic]] complications
|-
! align="center" style="background:#DCDCDC;" + |[[Glucocorticoids]]<ref name="NeelSnyder2012">{{cite journal|last1=Neel|first1=Jennifer A.|last2=Snyder|first2=Laura|last3=Grindem|first3=Carol B.|title=Thrombocytosis: a retrospective study of 165 dogs|journal=Veterinary Clinical Pathology|volume=41|issue=2|year=2012|pages=216–222|issn=02756382|doi=10.1111/j.1939-165X.2012.00416.x}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* Stimulate megakaryocytopoiesis
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="Left" style="background:#F5F5F5;" + |
* [[Cancer|Malignancy]]
* [[Autoimmunity|Autoimmune diseases]]
| align="center" style="background:#F5F5F5;" + | +
| align="Left" style="background:#F5F5F5;" + |
* [[Obesity|Obese]]
| align="Left" style="background:#F5F5F5;" + |
* Easy [[Bruise|bruising]]
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="Left" style="background:#F5F5F5;" + |
* [[Abdominal pain]]
* [[Muscle weakness]]
* [[Growth failure]]
* [[Pubertal delay]]
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* [[Myelofibrosis|Megakaryocytic]] fragments
* Large numbers of microspherocytes
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + |Nl to ↑
| align="center" style="background:#F5F5F5;" + |Nl to ↑
| align="Left" style="background:#F5F5F5;" + |
* Depends on the etiology
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + history of drug consumption
| align="Left" style="background:#F5F5F5;" + |
* [[Thrombosis|Thromboembolic]] complications
* [[Cushing's syndrome|Cushing syndrome]]
* [[Diabetes mellitus]]
|-
! align="center" style="background:#DCDCDC;" + |[[Antibiotic|Antibiotics]]<ref name="pmid23111864">{{cite journal |vauthors=Scharf RE |title=Drugs that affect platelet function |journal=Semin. Thromb. Hemost. |volume=38 |issue=8 |pages=865–83 |date=November 2012 |pmid=23111864 |doi=10.1055/s-0032-1328881 |url=}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* Unclear
* Stimulate megakaryocytopoiesis
* [[Acute phase protein|Acute phase reactant]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="Left" style="background:#F5F5F5;" + |
* [[Infection]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="Left" style="background:#F5F5F5;" + |
* Depends on the etiology
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* [[Myelofibrosis|Megakaryocytic]] fragments
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="Left" style="background:#F5F5F5;" + |
* Depends on the etiology
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + history of drug consumption
| align="Left" style="background:#F5F5F5;" + |
* Poor prognosis
* [[Thrombosis]]
|-
! align="center" style="background:#DCDCDC;" + |[[Thrombopoietin]]<ref name="pmid24499199">{{cite journal |vauthors=Hitchcock IS, Kaushansky K |title=Thrombopoietin from beginning to end |journal=Br. J. Haematol. |volume=165 |issue=2 |pages=259–68 |date=April 2014 |pmid=24499199 |doi=10.1111/bjh.12772 |url=}}</ref><ref name="TeofiliGiona2010">{{cite journal|last1=Teofili|first1=Luciana|last2=Giona|first2=Fiorina|last3=Martini|first3=Maurizio|last4=Torti|first4=Lorenza|last5=Cenci|first5=Tonia|last6=Foà|first6=Robin|last7=Leone|first7=Giuseppe|last8=Larocca|first8=Luigi M.|title=Thrombopoietin Receptor Activation, Thrombopoietin Mimetic Drugs, and Hereditary Thrombocytosis: Remarks on Bone Marrow Fibrosis|journal=Journal of Clinical Oncology|volume=28|issue=19|year=2010|pages=e317–e318|issn=0732-183X|doi=10.1200/JCO.2010.29.0387}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* Stimulate megakaryocytopoiesis
* Thrombopoiesis
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="Left" style="background:#F5F5F5;" + |
* [[Malignancy]]
* [[Chemotherapy]]
| align="center" style="background:#F5F5F5;" + | +
| align="Left" style="background:#F5F5F5;" + |
* Chronically ill
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Nl to ↑
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="Left" style="background:#F5F5F5;" + |
* Depends on the etiology
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* [[Myelofibrosis|Megakaryocytic]] fragments
* Large [[Platelet|platelets]]
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="Left" style="background:#F5F5F5;" + |
* Depends on the etiology
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + history of drug consumption
| align="Left" style="background:#F5F5F5;" + |
* Poor prognosis
* [[Thrombosis]]
|-
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Increased megakaryocyte proliferation
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Accelerated platelet release
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Reduced platelet turnover
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
! rowspan="3" align="center" style="background:#DCDCDC;" + |Other
! align="center" style="background:#DCDCDC;" + |Post-splenectomy or functional [[asplenia]]<ref name="pmid22203487">{{cite journal |vauthors=Vlachaki E, Kalogeridis A, Neokleous N, Perifanis V, Klonizakis F, Ioannidou E, Klonizakis I |title=Absence of JAK2V617F mutation in patients with beta-thalassemia major and thrombocytosis due to splenectomy |journal=Mol. Biol. Rep. |volume=39 |issue=5 |pages=6101–5 |date=May 2012 |pmid=22203487 |doi=10.1007/s11033-011-1425-7 |url=}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* Reduced [[platelet]] turnover
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="Left" style="background:#F5F5F5;" + |
* Prior surgical removal of the spleen
* [[Sickle-cell disease|Sickle cell disease]]
| align="center" style="background:#F5F5F5;" + |±
| align="Left" style="background:#F5F5F5;" + |
* Normal
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |[[Asplenia]]
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* [[Howell-Jolly body|Howell-Jolly bodies]]
* Nucleated [[Red blood cell|RBCs]]
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="Left" style="background:#F5F5F5;" + |
* Small or no [[spleen]] on [[CT scan]]
| align="center" style="background:#F5F5F5;" + |Clinical manifestation
| align="Left" style="background:#F5F5F5;" + |
* Incidental laboratory finding
* [[Thrombosis]]
|-
! align="center" style="background:#DCDCDC;" + |[[Allergy|Allergic reactions]]<ref name="pmid8603285">{{cite journal |vauthors=Randi ML, Rossi C, Fabris F, Zerbinati P, Girolami A |title=Atopic dermatitis and allergic diseases with thrombocytosis: a possible link |journal=Ann. Allergy Asthma Immunol. |volume=75 |issue=6 Pt 1 |pages=530–2 |date=December 1995 |pmid=8603285 |doi= |url=}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* Unknown
* Activation of chloride transport
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="Left" style="background:#F5F5F5;" + |
* [[Anaphylaxis]]
* [[Respiratory disease|Respiratory diseases]]
| align="center" style="background:#F5F5F5;" + | -
| align="Left" style="background:#F5F5F5;" + |
* Acutely ill
* Diaphoretic
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="Left" style="background:#F5F5F5;" + |
* [[Dizziness]]
* [[Tremor]]
* [[Anxiety]]
* [[Dyspnea]]
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* [[Myelofibrosis|Megakaryocytic]] fragments
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="Left" style="background:#F5F5F5;" + |
* Depends on the etiology
| align="center" style="background:#F5F5F5;" + |Clinical manifestation
| align="Left" style="background:#F5F5F5;" + |
* Poor prognosis
|-
! align="center" style="background:#DCDCDC;" + |[[Physical exercise|Exercise]]<ref name="pmid25573725">{{cite journal |vauthors=Beck WR, Scariot PP, Gobatto CA |title=Primary and secondary thrombocytosis induced by exercise and environmental luminosity |journal=Bratisl Lek Listy |volume=115 |issue=10 |pages=607–10 |date=2014 |pmid=25573725 |doi= |url=}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* Increased [[megakaryocyte]] proliferation
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Athlete
| align="Left" style="background:#F5F5F5;" + |
* Exercise
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Normal
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* [[Myelofibrosis|Megakaryocytic]] fragments
| align="Left" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="Left" style="background:#F5F5F5;" + |
* Depends on the etiology
| align="center" style="background:#F5F5F5;" + |Clinical manifestation
| align="center" style="background:#F5F5F5;" + |NA
|-
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pseudothrombocytosis
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Cryoglobulinemia|Mixed cryoglobulinemia]]<ref name="pmid3818970">{{cite journal |vauthors=Patel KJ, Hughes CG, Parapia LA |title=Pseudoleucocytosis and pseudothrombocytosis due to cryoglobulinaemia |journal=J. Clin. Pathol. |volume=40 |issue=1 |pages=120–1 |date=January 1987 |pmid=3818970 |pmc=1140844 |doi= |url=}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* Falsely elevated
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Any
| align="Left" style="background:#F5F5F5;" + |
* [[Cancer|Malignancy]]
* [[Autoimmune disease]]
* [[Infection]]
| align="center" style="background:#F5F5F5;" + | -
| align="Left" style="background:#F5F5F5;" + |
* Atypical cutaneous ulcers
* Palpable [[purpura]]
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="Left" style="background:#F5F5F5;" + |
* [[Headache]]
* [[Confusion]]
* Blurry or loss of [[Visual system|vision]]
* [[Arthralgia|Joint pain]]
* Generalized [[Muscle weakness|weakness]]
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + |↑
| align="Left" style="background:#F5F5F5;" + |
* Cytoplasmic fragments
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |[[Skin biopsy]]
| align="Left" style="background:#F5F5F5;" + |
* [[Vasculitis]]
* [[Neuropathy]]
* [[Raynaud's phenomenon|Raynaud phenomenon]]
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Cytoplasmic fragments<ref name="AkinciHacibekiroglu2013">{{cite journal|last1=Akinci|first1=Sema|last2=Hacibekiroglu|first2=Tuba|last3=Basturk|first3=Abdulkadir|last4=Bakanay|first4=Sule Mine|last5=Guney|first5=Tekin|last6=Dilek|first6=Imdat|title=Pseudothrombocytosis due to Microerythrocytosis: A Case of Beta Thalassemia Minor Complicated with Iron Deficiency Anemia|journal=Acta Haematologica|volume=130|issue=2|year=2013|pages=61–63|issn=1421-9662|doi=10.1159/000346434}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* Falsely elevated
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Normal
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="Left" style="background:#F5F5F5;" + |
* Cytoplasmic fragments
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Repeat
| align="center" style="background:#F5F5F5;" + |NA
|}


[[Category:Needs content]]
==References==
{{reflist|2}}

Latest revision as of 16:45, 2 October 2018

Thrombocytosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thrombocytosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thrombocytosis differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thrombocytosis differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thrombocytosis differential diagnosis

CDC on Thrombocytosis differential diagnosis

Thrombocytosis differential diagnosis in the news

Blogs on Thrombocytosis differential diagnosis

Directions to Hospitals Treating Thrombocytosis

Risk calculators and risk factors for Thrombocytosis differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]

Overview

Thrombocytosis Differential Diagnosis

Differentiating the diseases that can cause thrombocytosis :

Category Condition Etiology Mechanism Inherited Acquried Clinical manifestations Para−clinical findings Gold standard Associated findings
Demography History Symptoms Signs
Lab Findings Imaging
Fever Appearance Bleeding BP Splenomegaly Jaundice Other CBC PBS Bone marrow exam PT PTT
Increased megakaryocyte proliferation Accelerated platelet release Reduced platelet turnover Plt HB WBC
Autonomous thrombocytosis Hematologic malignancies Essential thrombocythemia[1]
  • Acquired mutation of JAK2, CALR, or MPL
+ - - - + Mean age >60 years old, female > male ±
  • Flushing
+ Nl + - ↑↑ Nl Nl Bone marrow biopsy
  • Thrombo-hemorrhagic complications
Polycythemia vera[2]
  • Acquired mutation of JAK2
+ - - - + Mean age >60 years old -
  • Facial plethora
± Nl + - ↑↑ Bone marrow biopsy
  • Thrombo-hemorrhagic complications
Primary myelofibrosis[3] + - - - + Mean age >60 years old, male> female - + Nl + + ↑/↓ Bone marrow biopsy
  • Thrombo-hemorrhagic complications
  • Variable risk for development of acute leukemia
Chronic myeloid leukemia[4] + - - - + Mean age >50 years old, male> female History of exposure to: + + Nl + -
  • ↑ Proportion of metamyelocytes and other white blood cells at various stages of maturation
Bone marrow biopsy
  • Increase of immature myeloid cells
Acute myeloid leukemia[5]
  • Unknown
+ - - - + Median age of 63 years old + + Nl + + ↑/↓ ↑/↓ NA Bone marrow examination + clinical manifestation
Myelodysplastic syndromes[6] + - - ± + Elderly Exposure to: ± + Nl + + ↑/↓ Nl Nl NA Bone marrow examination + clinical manifestation
Condition Etiology Increased megakaryocyte proliferation Accelerated platelet release Reduced platelet turnover Inherited Acquried Demography History Fever Appearance Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam PT PTT Imaging Gold standard Associated findings
Familial thrombocytosis[7][8] + - - + - Rare familial disease, middle age male and female -
  • Normal
- Nl - - - Nl Nl Nl Nl NA Genetic study
Reactive thrombocytosis Anemia/

blood loss[9]

+ - - - + Any - + Nl to ↓ - - Depends on the etilogy Nl Nl Nl NA Clinical manifestation
  • Required iron studies
Infection Chronic infections + + - - + Any + ± Nl to ↓ - ± Depends on the etilogy Nl Nl
  • Depends on the etiology
Culture Depends on the etilogy
Tuberculosis + + - - + Any
  • History of close contact
+
  • Cachectic
- Nl - - Nl Nl Nl
  • Cavitation on chest imaging
Clinical manifestation+ culture
Acute bacterial and viral infections + + - - + Any
  • History of close contact
+
  • Acutely ill
- Nl - - Depends on the etilogy Nl Nl
  • Depends on the etiology
Clinical manifestation+ culture
  • Depends on the etiology
Inflammation Vasculitides[10]
  • Unknown
+ + - ± + Any
  • Family history of rheumatologic disorders
+
  • Acutely ill
+ Nl - - Nl to ↓ Nl to ↑ Nl to ↑
  • Depends on the type
Clinical manifestation+ culture
  • Depends on the type
Acute pancreatitis + + - - + Any +
  • Acutely ill
- Nl to ↓ - + Nl to ↓ Nl to ↑ Nl to ↑ Clinical manifestation
Malignancy[11] + + - ± ± Any
  • Prior malignancy
  • Exposure to chemicals
  • Family history of malignancy
+
  • Cachectic
- Nl to ↓ Depends on the type -
  • Tenderness
Nl to ↓ Nl to ↑ Nl to ↑
  • Depends on the type
Biopsy
Condition Etiology Increased megakaryocyte proliferation Accelerated platelet release Reduced platelet turnover Inherited Acquried Demography History Fever Appearance Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam PT PTT Imaging Gold standard Associated findings
Tissue damage Thermal burns[12] - + - - + Any
  • Thermal burn
+
  • Acutely ill
± Nl to ↓ - ± Nl to ↓ Nl to ↑ Nl to ↑
  • Depend on the involvement
Clinical manifestation
Trauma[13] - + - - + Any ±
  • Acutely ill
± Nl to ↓ - - Nl to ↓ Nl Nl
  • Depend on the involvement
  • Fracture on X-rays
Clinical manifestation
  • Sepsis
  • Associated with higher rates of complications
Myocardial infarction[14] - + - - + Elderly ±
  • Acutely ill
  • Diaphoretic
- Nl to ↓ - - Nl to ↓ Nl Nl Clinical manifestation + enzymes elevation
Medication[15] Vincristine[16] - + - - + Any -
  • Cachectic
- Nl + - Nl to ↓ Nl to ↑ Nl to ↑
  • Depends on the etiology
Clinical manifestation + history of drug consumption
Epinephrine[17]
  • Unknown
  • Activation of chloride transport
+ + - - + Any -
  • Acutely ill
  • Diaphoretic
- Nl to ↓ - - Nl Nl
  • Depends on the etiology
Clinical manifestation + history of drug consumption
Glucocorticoids[18]
  • Stimulate megakaryocytopoiesis
+ + - - + Any + Nl to ↓ - - Nl to ↓ Nl to ↑ Nl to ↑
  • Depends on the etiology
Clinical manifestation + history of drug consumption
Antibiotics[19] + + - - + Any + Nl ± Nl - -
  • Depends on the etiology
Nl Nl Nl
  • Depends on the etiology
Clinical manifestation + history of drug consumption
Thrombopoietin[20][21]
  • Stimulate megakaryocytopoiesis
  • Thrombopoiesis
+ - - - + Any +
  • Chronically ill
- Nl to ↑ - -
  • Depends on the etiology
Nl Nl
  • Depends on the etiology
Clinical manifestation + history of drug consumption
Condition Etiology Increased megakaryocyte proliferation Accelerated platelet release Reduced platelet turnover Inherited Acquried Demography History Fever Appearance Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam PT PTT Imaging Gold standard Associated findings
Other Post-splenectomy or functional asplenia[22] - - + - + Any ±
  • Normal
+ Nl Asplenia - - Nl Nl Clinical manifestation
Allergic reactions[23]
  • Unknown
  • Activation of chloride transport
+ + - - + Any -
  • Acutely ill
  • Diaphoretic
- Nl to ↓ - - Nl Nl
  • Depends on the etiology
Clinical manifestation
  • Poor prognosis
Exercise[24] + + - - + Athlete
  • Exercise
- Normal - Nl - - NA Nl Nl
  • Depends on the etiology
Clinical manifestation NA
Pseudothrombocytosis Mixed cryoglobulinemia[25]
  • Falsely elevated
- - - - - Any -
  • Atypical cutaneous ulcers
  • Palpable purpura
- Nl - - Nl to ↓
  • Cytoplasmic fragments
Nl Nl Nl NA Skin biopsy
Cytoplasmic fragments[26]
  • Falsely elevated
- - - - - Any NA - Normal - Nl - - NA Nl Nl
  • Cytoplasmic fragments
Nl Nl Nl Nl Repeat NA

References

  1. Brière, Jean B (2007). Orphanet Journal of Rare Diseases. 2 (1): 3. doi:10.1186/1750-1172-2-3. ISSN 1750-1172. Missing or empty |title= (help)
  2. Arber, D. A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M. J.; Le Beau, M. M.; Bloomfield, C. D.; Cazzola, M.; Vardiman, J. W. (2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): 2391–2405. doi:10.1182/blood-2016-03-643544. ISSN 0006-4971.
  3. Tefferi, Ayalew; Lasho, Terra L.; Jimma, Thitina; Finke, Christy M.; Gangat, Naseema; Vaidya, Rakhee; Begna, Kebede H.; Al-Kali, Aref; Ketterling, Rhett P.; Hanson, Curtis A.; Pardanani, Animesh (2012). "One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience". Mayo Clinic Proceedings. 87 (1): 25–33. doi:10.1016/j.mayocp.2011.11.001. ISSN 0025-6196.
  4. Thompson, Philip A.; Kantarjian, Hagop M.; Cortes, Jorge E. (2015). "Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015". Mayo Clinic Proceedings. 90 (10): 1440–1454. doi:10.1016/j.mayocp.2015.08.010. ISSN 0025-6196.
  5. Rose-Inman, Hayley; Kuehl, Damon (2014). "Acute Leukemia". Emergency Medicine Clinics of North America. 32 (3): 579–596. doi:10.1016/j.emc.2014.04.004. ISSN 0733-8627.
  6. Natelson, Ethan A.; Pyatt, David (2013). "Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog". Advances in Hematology. 2013: 1–11. doi:10.1155/2013/309637. ISSN 1687-9104.
  7. Ding, J. (2004). "Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin". Blood. 103 (11): 4198–4200. doi:10.1182/blood-2003-10-3471. ISSN 0006-4971.
  8. Wiestner, A.; Padosch, S. A.; Ghilardi, N.; Cesar, J. M.; Odriozola, J.; Shapiro, A.; Skoda, R. C. (2000). "Hereditary thrombocythaemia is a genetically heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary thrombocythaemia". British Journal of Haematology. 110 (1): 104–109. doi:10.1046/j.1365-2141.2000.02169.x. ISSN 0007-1048.
  9. Kuter, David J. (1996). "The Physiology of Platelet Production". Stem Cells. 14 (S1): 88–101. doi:10.1002/stem.5530140711. ISSN 1066-5099.
  10. Hamblin T, Oscier D (September 1978). "Polyarteritis presenting with thrombocytosis and palliated by plasma exchange". Postgrad Med J. 54 (635): 615–7. PMC 2425233. PMID 82963.
  11. Yang, Chen; Jiang, Hui; Huang, Shaozhuo; Hong, Hui; Huang, Xiaowen; Wang, Xiaojie; Liao, Weixin; Wang, Xueyi; Chen, Xuewen; Jiang, Liming (2018). "The prognostic role of pretreatment thrombocytosis in gastric cancer". Medicine. 97 (31): e11763. doi:10.1097/MD.0000000000011763. ISSN 0025-7974.
  12. Dinsdale, R. J.; Devi, A.; Hampson, P.; Wearn, C. M.; Bamford, A. L.; Hazeldine, J.; Bishop, J.; Ahmed, S.; Watson, C.; Lord, J. M.; Moiemen, N.; Harrison, P. (2017). "Changes in novel haematological parameters following thermal injury: A prospective observational cohort study". Scientific Reports. 7 (1). doi:10.1038/s41598-017-03222-w. ISSN 2045-2322.
  13. Salim, Ali; Hadjizacharia, Pantelis; DuBose, Joseph; Kobayashi, Leslie; Inaba, Kenji; Chan, Linda S.; Margulies, Daniel R. (2009). "What is the Significance of Thrombocytosis in Patients With Trauma?". The Journal of Trauma: Injury, Infection, and Critical Care. 66 (5): 1349–1354. doi:10.1097/TA.0b013e318191b8af. ISSN 0022-5282.
  14. Nanavati, Amit; Patel, Nainesh; Burke, James (2012). "Thrombocytosis and Coronary Occlusion". JACC: Cardiovascular Interventions. 5 (6): e18–e19. doi:10.1016/j.jcin.2011.12.018. ISSN 1936-8798.
  15. Frye JL, Thompson DF (February 1993). "Drug-induced thrombocytosis". J Clin Pharm Ther. 18 (1): 45–8. PMID 8473359.
  16. Feliu, E.; Cervantes, F.; Blade, J.; Rozman, C. (1980). "Thrombocytosis in Quiescent Chronic Granulocytic Leukaemia after Vincristine and 6-Mercaptopurine Therapy". Acta Haematologica. 64 (4): 224–226. doi:10.1159/000207258. ISSN 0001-5792.
  17. Spalding A, Vaitkevicius H, Dill S, MacKenzie S, Schmaier A, Lockette W (February 1998). "Mechanism of epinephrine-induced platelet aggregation". Hypertension. 31 (2): 603–7. PMID 9461228.
  18. Neel, Jennifer A.; Snyder, Laura; Grindem, Carol B. (2012). "Thrombocytosis: a retrospective study of 165 dogs". Veterinary Clinical Pathology. 41 (2): 216–222. doi:10.1111/j.1939-165X.2012.00416.x. ISSN 0275-6382.
  19. Scharf RE (November 2012). "Drugs that affect platelet function". Semin. Thromb. Hemost. 38 (8): 865–83. doi:10.1055/s-0032-1328881. PMID 23111864.
  20. Hitchcock IS, Kaushansky K (April 2014). "Thrombopoietin from beginning to end". Br. J. Haematol. 165 (2): 259–68. doi:10.1111/bjh.12772. PMID 24499199.
  21. Teofili, Luciana; Giona, Fiorina; Martini, Maurizio; Torti, Lorenza; Cenci, Tonia; Foà, Robin; Leone, Giuseppe; Larocca, Luigi M. (2010). "Thrombopoietin Receptor Activation, Thrombopoietin Mimetic Drugs, and Hereditary Thrombocytosis: Remarks on Bone Marrow Fibrosis". Journal of Clinical Oncology. 28 (19): e317–e318. doi:10.1200/JCO.2010.29.0387. ISSN 0732-183X.
  22. Vlachaki E, Kalogeridis A, Neokleous N, Perifanis V, Klonizakis F, Ioannidou E, Klonizakis I (May 2012). "Absence of JAK2V617F mutation in patients with beta-thalassemia major and thrombocytosis due to splenectomy". Mol. Biol. Rep. 39 (5): 6101–5. doi:10.1007/s11033-011-1425-7. PMID 22203487.
  23. Randi ML, Rossi C, Fabris F, Zerbinati P, Girolami A (December 1995). "Atopic dermatitis and allergic diseases with thrombocytosis: a possible link". Ann. Allergy Asthma Immunol. 75 (6 Pt 1): 530–2. PMID 8603285.
  24. Beck WR, Scariot PP, Gobatto CA (2014). "Primary and secondary thrombocytosis induced by exercise and environmental luminosity". Bratisl Lek Listy. 115 (10): 607–10. PMID 25573725.
  25. Patel KJ, Hughes CG, Parapia LA (January 1987). "Pseudoleucocytosis and pseudothrombocytosis due to cryoglobulinaemia". J. Clin. Pathol. 40 (1): 120–1. PMC 1140844. PMID 3818970.
  26. Akinci, Sema; Hacibekiroglu, Tuba; Basturk, Abdulkadir; Bakanay, Sule Mine; Guney, Tekin; Dilek, Imdat (2013). "Pseudothrombocytosis due to Microerythrocytosis: A Case of Beta Thalassemia Minor Complicated with Iron Deficiency Anemia". Acta Haematologica. 130 (2): 61–63. doi:10.1159/000346434. ISSN 1421-9662.